Michael Partridge - Vertex Pharmaceuticals Vice President - Investor Relations

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>VRT</div>
VRTX -- USA Stock  

Fiscal Quarter End: March 31, 2020  

We currently do not have informatin regarding Michael Partridge. This executive tanure with Vertex Pharmaceuticals Incorpor is not currenlty determined.
617 341-6100  www.vrtx.com

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Christopher FenimoreRegeneron Pharmaceuticals
Ronald JanishPerrigo Company Plc
George YancopoulosRegeneron Pharmaceuticals
Marc CouckePerrigo Company Plc
Jeffrey NeedhamPerrigo Company Plc
K RaoDr Reddys Laboratories Ltd
Roxanne LaganoZoetis
Svend AndersenPerrigo Company Plc
Joyce LeeZoetis
Alok SonigDr Reddys Laboratories Ltd
James MichaudPerrigo Company Plc
Scott JamisonPerrigo Company Plc
Amit BiswasDr Reddys Laboratories Ltd
Joseph LaRosaRegeneron Pharmaceuticals
Daniel PlewRegeneron Pharmaceuticals
Douglas BoothePerrigo Company Plc
Michael StewartPerrigo Company Plc
Jatin ShahPerrigo Company Plc
Thomas FarringtonPerrigo Company Plc
Jay MarkowitzRegeneron Pharmaceuticals
J RamachandranDr Reddys Laboratories Ltd

Company Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for the treatment of cystic fibrosis . The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 3000 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 3,000 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent DirectorView
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical OfficerView
Michael Parini, Executive Vice President and Chief Legal OfficerView
Alan Garber, Independent DirectorView
Joshua Boger, Executive Director and Chairman of Science and Technology CommitteeView
John Gray, Senior Vice President Genetic TherapiesView
Margaret McGlynn, Independent DirectorView
Sangeeta Bhatia, DirectorView
Terrence Kearney, Independent DirectorView
Ian Smith, CFO, Executive Vice PresidentView
Paul Silva, Senior Vice President Corporate ControllerView
David Altshuler, Independent DirectorView
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines DevelopmentView
Elaine Ullian, Co-Lead Independent DirectorView
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and ValueView
David Greenway, DirectorView
Charles Wagner, CFO, Executive Vice PresidentView
Bruce Sachs, Co-Lead Independent DirectorView
Lloyd Carney, Independent DirectorView
Michael Partridge, Vice President - Investor RelationsView
Yuchun Lee, Independent DirectorView
Kimberly White, Senior Vice President and Chief Communications OfficerView
Stuart Arbuckle, Chief Commercial Officer and Executive VPView
Thomas Graney, CFO, Senior Vice PresidentView
Charles Milstein, Executive Vice President Chief Legal and Administrative OfficerView
Jeffrey Leiden, Chairman of the Board and Presidentident, CEOView

Stock Performance Indicators

Return On Equity24.14
Return On Asset0.0042
Profit Margin30.50
Operating Margin25.01
window.location = "/error404.html";